Table 1.

Baseline patient demographics stratified by AKI status

	No AKI Development	AKI Development	P
n	85	13
Age	54.02 (8.38)	55.77 (8.32)	0.49
Gender, n (%) male	46 (54)	6 (46)	0.78
Race, n (%) white	77 (91)	12 (92)	0.52
Etiology of cirrhosis, n (%)
HCV	10 (12)	3 (23)
HCV + alcohol	16 (19)	1 (8)
NASH	29 (34)	5 (38)	0.75
Alcohol	19 (22)	3 (23)
Other	11 (13)	1 (8)
Infection on admission, n (%)	18 (21)	5 (38)	0.18
History of ascites, n (%)	61 (72)	12 (92)	0.17
History of HE, n (%)	58 (68)	11 (85)	0.19
History of PHTN bleed, n (%)	13 (15)	1 (8)	0.69
DM, n (%)	35 (41)	6 (46)	0.77
HTN, n (%)	29 (34)	5 (38)	0.76
MAP	84.08 (12.90)	80.38 (11.78)	0.33
Baseline creatinine, mg/dL	0.94 (0.35)	0.99 (0.30)	0.60
Baseline eGFR, mL·min−1·1.73 m−2*	86.06 (26.86)	76.77 (21.34)	0.23
Admit creatinine, mg/dL	0.98 (0.38)	1.08 (0.41)	0.39
Admit eGFR, mL·min−1·1.73 m−2*	82.82 (27.01)	73.62 (26.82)	0.26
Admit sodium, mmol/L	133.56 (12.00)	132.54 (6.62)	0.65
Admit albumin, g/dL	2.94 (0.62)	2.51 (0.57)	0.02
Admit total bilirubin, mg/dL	4.19 (4.95)	2.84 (2.60)	0.14
Admit WBC, 109/L	6.98 (4.50)	7.92 (3.84)	0.48
Admit INR	1.65 (0.58)	1.61 (0.57)	0.84
CTP score	9.31 (2.10)	9.77 (1.88)	0.45
CTP class, n (%)
A	10 (12)	0 (0)
B	33 (39)	6 (46)	0.57
C	42 (49)	7 (54)
MELD-sodium score	19.27 (6.22)	20.23 (6.37)	0.61

AKI, acute kidney injury; CTP, Child Turcotte Pugh; DM, diabetes mellitus; eGFR, estimated glomerular filtration rate; HCV, hepatitis C; HE, hepatic encephalopathy; HTN, hypertension; INR, international normalized ratio; MAP, mean arterial pressure; MELD, Model for Endstage Liver Disease; NASH, nonalcoholic steatohepatitis; PTHN, portal hypertension; WBC, white blood cell.

^*Based on Chronic Kidney Disease Epidemiology Collaboration creatinine equation (24).